## October 31, 2021 Analysis of EU national data

Summary: In the past few weeks,
daily growth rates for cases have increased significantly in
the majority of European nations, meaning that infection
rates are growing rapidly.
This fall resurgence has not been seen in Canada or the US.

See the October 24 report that shows the
comparison of growth rates then and 4 weeks prior
for US states, Canadian provinces, and European nations.
The situation in Europe is very concerning, showing an increase in
growth rates by about 5%/day or more, for most countries.
In the past week, the high case growth rates have not substantially declined.

US and Canadian studies are posted [here](../index.md).

## Fits to case data

The plots below show the case and death data for 29 EU nations.
The data fits were done using data up until October 30, 2021.

The large green, grey, and indigo circles are the daily cases, hospital admissions, and deaths respectively, averaged over each week.
The smaller points show the daily values.
The case data are used to define the periods for which transmission rate appears to be constant.
The vertical lines show where the transmission rate is changed.

Since the rapid growth in daily cases in many countries will lead to very high numbers, it is
expected that measures will be brought in to reverse that trend.
Vertical lines in the future show hypothetical dates in which such measures might be
introduced.
The subsequent reduction in growth rate is a result of those changes.
Future forecasts will delay those transitions, if no measures are introduced.

If the susceptible fraction is roughly constant, constant transmission rates
lead to steady exponential growth or decline during, which appear as straight lines on
these log-scale plots.
With immunity growing, these lines are no longer straight - bending downwards due to the herd effect.
The solid curves show the model expectations for cases, hospital admissions, and deaths, as determined from
the case data.

The fraction of infections that lead to hospitalization or death are calibrated only to recent data.
The extent that the model projection curves match earlier hospitalization and death data
indicates whether probabilities for infections leads to severe disease is changing or not.

Since this analysis started in July, fine tuning of the model for dates prior to May was not done, resulting in
some discrepency with data.

The dashed curves separately show the reported cases interpretted as coming
from variants of
concern, divided into two types B.1.1.7 (alpha) and B.1.617.2 (delta).
The very rapid growth of cases is a combination of relaxing restrictions and the introduction of the delta variant.

### [Austria](img/at_2_9_1031.pdf)

![at](img/at_2_9_1031.png)

### [Belgium](img/be_2_9_1031.pdf)

![be](img/be_2_9_1031.png)

### [Bulgaria](img/bg_2_9_1031.pdf)

![bg](img/bg_2_9_1031.png)

### [Croatia](img/hr_2_9_1031.pdf)

![hr](img/hr_2_9_1031.png)

### [Cyprus](img/cy_2_9_1031.pdf)

![cy](img/cy_2_9_1031.png)

### [Czechia](img/cz_2_9_1031.pdf)

![cz](img/cz_2_9_1031.png)

### [Denmark](img/dk_2_9_1031.pdf)

![dk](img/dk_2_9_1031.png)

### [Estonia](img/ee_2_9_1031.pdf)

![ee](img/ee_2_9_1031.png)

### [Finland](img/fi_2_9_1031.pdf)

![fi](img/fi_2_9_1031.png)

### [France](img/fr_2_9_1031.pdf)

![fr](img/fr_2_9_1031.png)

### [Germany](img/de_2_9_1031.pdf)

![de](img/de_2_9_1031.png)

### [Greece](img/gr_2_9_1031.pdf)

![gr](img/gr_2_9_1031.png)

### [Hungary](img/hu_2_9_1031.pdf)

![hu](img/hu_2_9_1031.png)

### [Ireland](img/ie_2_9_1031.pdf)

![ie](img/ie_2_9_1031.png)

### [Italy](img/it_2_9_1031.pdf)

![it](img/it_2_9_1031.png)

### [Latvia](img/lv_2_9_1031.pdf)

![lv](img/lv_2_9_1031.png)

### [Lithuania](img/lt_2_9_1031.pdf)

![lt](img/lt_2_9_1031.png)

### [Luxembourg](img/lu_2_9_1031.pdf)

![lu](img/lu_2_9_1031.png)

### [Netherlands](img/nl_2_9_1031.pdf)

![nl](img/nl_2_9_1031.png)

### [Norway](img/no_2_9_1031.pdf)

![no](img/no_2_9_1031.png)

### [Poland](img/pl_2_9_1031.pdf)

![pl](img/pl_2_9_1031.png)

### [Portugal](img/pt_2_9_1031.pdf)

![pt](img/pt_2_9_1031.png)

### [Romania](img/ro_2_9_1031.pdf)

![ro](img/ro_2_9_1031.png)

### [Slovakia](img/sk_2_9_1031.pdf)

![sk](img/sk_2_9_1031.png)

### [Slovenia](img/si_2_9_1031.pdf)

![si](img/si_2_9_1031.png)

### [Spain](img/es_2_9_1031.pdf)

![es](img/es_2_9_1031.png)

### [Sweden](img/se_2_9_1031.pdf)

![se](img/se_2_9_1031.png)

### [Switzerland](img/ch_2_9_1031.pdf)

![ch](img/ch_2_9_1031.png)

### [United Kingdom](img/gb_2_9_1031.pdf)

![gb](img/gb_2_9_1031.png)

## Comparing prevalence between countries

The following plots show the daily cases per 100,000 people in each country, grouped according to geographical regions.

![prev](img/EU_2_9_1031_prevalence.png)

## [return to case studies](../index.md)

